Private equity firms The Carlyle Group, Signet Healthcare and OrbiMed have partially exited their investment in India-based pharmaceutical company Claris Lifesciences by participating in the company’s buyback offer. Claris Lifesciences offered a buyback issue worth INR2.3 billion (approximately US$39 million) in March 2014. The buyback was offered at a price of INR250 (approximately US$4.23) per share. The Carlyle Group sold a 1.74 percent stake, while OrbiMed and Signet sold a 0.64 percent and 0.34 percent stake, respectively, of the post-buyback capital base. The Carlyle Group, structured through its fund First Carlyle Ventures III, originally invested US$20 million in 2006.